A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Photodynamic therapy (PDT) is a form of phototherapy using nontoxic light-sensitive compounds (photosensitizers) that are exposed selectively to light at a controlled wavelength, laser intensity, and irradiation time, whereupon they generate toxic reactive oxygen species (ROS) that target malignant and other diseased cells. Oxygen is thus required for activity, lowering efficacy in highly developed tumors and other hypoxic environments. Selective apoptosis of diseased cells is difficult due to the radical nature of ROS, but may be controlled for through membrane potential and other cell-type specific properties' effects on permeability or through photoimmunotherapy. In developing any phototherapeutic agent, the phototoxicity of the treatment wavelength should be considered.
==== Chlorine tablets ==== Sodium dichloroisocyanurate or troclosene sodium, more commonly shortened as NaDCC, is a form of chlorine used for disinfection. It is used by major non-governmental organizations such as UNICEF to treat water in emergencies. Sodium dichloroisocyanurate tablets are available in a range of concentrations to treat differing volumes of water to give the World Health Organization's recommended 5ppm available chlorine. They are effervescent tablets allowing the tablet to dissolve in a matter of minutes.
Osedax antarcticus Glover, Wiklund & Dahlgren, 2013 Osedax bozoi Berman, Hiley, Read & Rouse, 2024 Osedax braziliensis Fujiwara, Jimi, Sumida, Kawato, Kitazato Osedax bryani Rouse, Goffredi, Johnson & Vrijenhoek Osedax byronbayensis Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax craigmcclaini Berman, Hiley, Read, Rouse, 2024 Osedax crouchi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax deceptionensis Taboada, Cristobo, Avila, Wiklund & Glover, 2013 Osedax docricketts Rouse, Goffredi, Johnson & Vrijenhoek Osedax estcourti Berman, Hiley, Read & Rouse, 2024 Osedax fenrisi Eilertsen, Dahlgren & Rapp, 2020 Osedax frankpressi Rouse, Goffredi & Vrijenhoek, 2004 Osedax jabba Rouse, Goffredi, Johnson & Vrijenhoek Osedax japonicus Fujikura, Fujiwara & Kawato, 2006 Osedax knutei Rouse, Goffredi, Johnson & Vrijenhoek Osedax lehmani Rouse, Goffredi, Johnson & Vrijenhoek Osedax lonnyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax mucofloris Glover, Kallstrom, Smith & Dahlgren, 2005 Osedax nataliae Gularte, Sumida, Bergamo & Rouse, 2024 Osedax nordenskjoeldi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax priapus Rouse et al., 2014 Osedax packardorum Rouse, Goffredi, Johnson & Vrijenhoek Osedax randyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax rogersi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax roseus Rouse, Worsaae, Johnson, Jones & Vrijenhoek, 2008 Osedax rubiplumus Rouse, Goffredi & Vrijenhoek, 2004 Osedax ryderi Rouse, Goffredi, Johnson & Vrijenhoek Osedax sigridae Rouse, Goffredi, Johnson & Vrijenhoek Osedax talkovici Rouse, Goffredi, Johnson & Vrijenhoek Osedax tiburon Rouse, Goffredi, Johnson & Vrijenhoek Osedax traceyae Berman, Hiley, Read & Rouse, 2024 Osedax ventana Rouse, Goffredi, Johnson & Vrijenhoek Osedax waadjum Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax westernflyer Rouse, Goffredi, Johnson & Vrijenhoek
Pizza Hut has sponsored the Book It! reading-incentive program since it started in January 1985. Students who read books according to the goal set by the classroom teacher, in any month from October through March, are rewarded with a Pizza Hut certificate good for a free, one-topping Personal Pan Pizza; and the classroom whose students read the most books is rewarded with a pizza party. A 1987 report estimated that children participating in the program increased their reading from three books to nine books per month, on average. The success of the classroom-based reading encouragement program spurred local libraries to create their own reading program during the summer months, when school is not in session. Book It! was conceived in 1984 during a dinner with Art Gunther, President of Pizza Hut, and Bud Gates, SVP of Marketing at Pizza Hut, as a way to help Gunther's son read more. The program has been criticized by some psychologists on the grounds it may lead to overjustification and reduce children's intrinsic interest in reading. Book It! was also criticized by the Campaign for a Commercial-Free Childhood in 2007 who described it as "one of corporate America's most insidious school-based brand promotions." A pamphlet produced by the group argued the program promoted junk food to a captive market, made teachers into promoters for Pizza Hut, and undermined parents by making visits to the chain an integral part of bringing up their children to be literate. However, a study of the program found participation in the program neither increased nor decreased reading motivation.
By 1988, only five proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA): synthetic insulin, human growth hormone, hepatitis B vaccine, alpha-interferon, and tissue plasminogen activator (TPa), for lysis of blood clots. By the end of the 1990s, however, 125 more genetically engineered drugs would be approved. The Great Recession led to several changes in the way the biotechnology industry was financed and organized. First, it led to a decline in overall financial investment in the sector, globally; and second, in some countries like the UK it led to a shift from business strategies focused on going for an initial public offering (IPO) to seeking a trade sale instead. By 2011, financial investment in the biotechnology industry started to improve again and by 2014 the global market capitalization reached $1 trillion. Genetic engineering also reached the agricultural front as well. There was tremendous progress since the market introduction of the genetically engineered Flavr Savr tomato in 1994. Ernst and Young reported that in 1998, 30% of the U.S. soybean crop was expected to be from genetically engineered seeds. In 1998, about 30% of the US cotton and corn crops were also expected to be products of genetic engineering. Genetic engineering in biotechnology stimulated hopes for both therapeutic proteins, drugs and biological organisms themselves, such as seeds, pesticides, engineered yeasts, and modified human cells for treating genetic diseases.
Sources: en.wikipedia.org
Radon has been produced commercially for use in radiation therapy, but for the most part has been replaced by radionuclides made in particle accelerators and nuclear reactors. Radon has been used in implantable seeds, made of gold or glass, primarily used to treat cancers, known as brachytherapy. The gold seeds were produced by filling a long tube with radon pumped from a radium source, the tube being then divided into short sections by crimping and cutting. The gold layer keeps the radon within, and filters out the alpha and beta radiations, while allowing the gamma rays to escape (which kill the diseased tissue). The activities might range from 0.05 to 5 millicuries per seed (2 to 200 MBq). The gamma rays are produced by radon and the first short-lived elements of its decay chain (218Po, 214Pb, 214Bi, 214Po). After 11 half-lives (42 days), radon radioactivity is at 1/2,048 of its original level. At this stage, the predominant residual activity of the seed originates from the radon decay product 210Pb, whose half-life (22.3 years) is 2,000 times that of radon and its descendants 210Bi and 210Po. 211Rn can be used to generate 211At, which has uses in targeted alpha therapy.
== Determining the RTD experimentally == Residence time distributions are measured by introducing a non-reactive tracer into the system at the inlet. Its input concentration is changed according to a known function and the output concentration measured. The tracer should not modify the physical characteristics of the fluid (equal density, equal viscosity) or the hydrodynamic conditions and it should be easily detectable. In general, the change in tracer concentration will either be a pulse or a step. Other functions are possible, but they require more calculations to deconvolute the RTD curve.
==== Reliable prediction of T-cell epitopes ==== A novel input representation has been developed consisting of a combination of sparse encoding, Blosum encoding, and input derived from hidden Markov models. This method predicts T-cell epitopes for the genome of hepatitis C virus and discuss possible applications of the prediction method to guide the process of rational vaccine design.
Both active and latent TB Intravenous drug users with Mantoux test above 10 mm HIV-positive people with Mantoux test above 5 mm Those who had close contact with TB patient and have Mantoux test above 5 mm As a preventative measure for those with pulmonary silicosis or fibrotic pulmonary lesions from recovered TB Isoniazid can be used alone or in combination with Rifampin for treatment of latent tuberculosis, or as part of a four-drug regimen.. The drug regimen typically requires daily or weekly oral administration for a period of three to nine months, often under Directly Observed Therapy (DOT) supervision.
Sources: en.wikipedia.org
In May 2009, Gil Kerlikowske, Director of the ONDCP – Obama's drug czar – indicated that the Obama administration did not plan to significantly alter drug enforcement policy, but that it would not use the term "war on drugs", considering it to be "counter-productive". In August 2010, Obama signed the Fair Sentencing Act into law, reducing the 100:1 sentencing disparity between crack and powder cocaine to 18:1 for pending and future cases. In 2013, Obama's Justice Department issued a policy memorandum known as the Cole Memo, stating that it would defer to state laws that authorize the production, distribution and possession of cannabis, "based on assurances that those states will impose an appropriately strict regulatory system." In 2011, the Global Commission on Drug Policy, an international non-governmental group composed primarily of former heads of state and government, and leaders from various sectors, released a report that stated, "The global war on drugs has failed." It recommended a paradigm shift, to a public health focus, with decriminalization for possession and personal use. Obama's ONDCP did not support the report, stating: "Drug addiction is a disease that can be successfully prevented and treated. Making drugs more available ... will make it harder to keep our communities healthy and safe."
exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved 2005/2012, discontinued in 2024 albiglutide (Tanzeum, manufactured by GSK), approved in 2014, discontinued in 2017 lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016, discontinued in 2023
Amino acids are the precursors to proteins. They join by condensation reactions to form short polymer chains called peptides or longer chains called either polypeptides or proteins. These chains are linear and unbranched, with each amino acid residue within the chain attached to two neighboring amino acids. In nature, the process of making proteins encoded by RNA genetic material is called translation and involves the step-by-step addition of amino acids to a growing protein chain by a ribozyme that is called a ribosome. The order in which the amino acids are added is read through the genetic code from an mRNA template, which is an RNA derived from one of the organism's genes. There are 22 amino acids that get naturally incorporated into polypeptides; these are called proteinogenic amino acids or natural amino acids. Of these, 20 are encoded by the universal genetic code. The remaining 2, selenocysteine and pyrrolysine, are incorporated into proteins by unique synthetic mechanisms. Selenocysteine is incorporated when the mRNA being translated includes a SECIS element, which causes the UGA codon to encode selenocysteine instead of a stop codon. Pyrrolysine is used by some methanogenic archaea in enzymes that they use to produce methane. It is coded for with the codon UAG, which is normally a stop codon in other organisms.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.